Cargando…
Development of Class IIa Bacteriocins as Therapeutic Agents
Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. There...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236453/ https://www.ncbi.nlm.nih.gov/pubmed/22187559 http://dx.doi.org/10.1155/2012/386410 |
_version_ | 1782218747024506880 |
---|---|
author | Lohans, Christopher T. Vederas, John C. |
author_facet | Lohans, Christopher T. Vederas, John C. |
author_sort | Lohans, Christopher T. |
collection | PubMed |
description | Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents. |
format | Online Article Text |
id | pubmed-3236453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32364532011-12-20 Development of Class IIa Bacteriocins as Therapeutic Agents Lohans, Christopher T. Vederas, John C. Int J Microbiol Review Article Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents. Hindawi Publishing Corporation 2012 2011-11-30 /pmc/articles/PMC3236453/ /pubmed/22187559 http://dx.doi.org/10.1155/2012/386410 Text en Copyright © 2012 C. T. Lohans and J. C. Vederas. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Lohans, Christopher T. Vederas, John C. Development of Class IIa Bacteriocins as Therapeutic Agents |
title | Development of Class IIa Bacteriocins as Therapeutic Agents |
title_full | Development of Class IIa Bacteriocins as Therapeutic Agents |
title_fullStr | Development of Class IIa Bacteriocins as Therapeutic Agents |
title_full_unstemmed | Development of Class IIa Bacteriocins as Therapeutic Agents |
title_short | Development of Class IIa Bacteriocins as Therapeutic Agents |
title_sort | development of class iia bacteriocins as therapeutic agents |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236453/ https://www.ncbi.nlm.nih.gov/pubmed/22187559 http://dx.doi.org/10.1155/2012/386410 |
work_keys_str_mv | AT lohanschristophert developmentofclassiiabacteriocinsastherapeuticagents AT vederasjohnc developmentofclassiiabacteriocinsastherapeuticagents |